Discontinued — last reported Q4 '25
D&A
Merck & Co. D&A increased by 180.6% to $1.49B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 186.0%, from $522.00M to $1.49B. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 17.9% CAGR.
Analysis
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
depreciation_and_amortization_cfHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $371.00M | $399.00M | $430.00M | $421.00M | $474.00M | $499.00M | $430.00M | $448.00M | $426.00M | $452.00M | $502.00M | $511.00M | $518.00M | $553.00M | $522.00M | $502.00M | $518.00M | $532.00M | $1.49B |
| QoQ Change | — | +7.5% | +7.8% | -2.1% | +12.6% | +5.3% | -13.8% | +4.2% | -4.9% | +6.1% | +11.1% | +1.8% | +1.4% | +6.8% | -5.6% | -3.8% | +3.2% | +2.7% | +180.6% |
| YoY Change | — | — | — | — | +27.8% | +25.1% | +0.0% | +6.4% | -10.1% | -9.4% | +16.7% | +14.1% | +21.6% | +22.3% | +4.0% | -1.8% | +0.0% | -3.8% | +186.0% |
Product Breakdown
| Segment | Q1 '23 | Q3 '23 |
|---|---|---|
| Alliance revenue - Lenvima | $72.00M | $81.00M |
| Total | $448.00M | $452.00M |
Alliance revenue - Lenvima was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Animal Health | $67.00M | $85.00M | $45.00M | $60.00M | $62.00M | $82.00M | $79.00M | $89.00M |
| Pharmaceutical | $1.00M | $1.00M | $2.00M | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M |
| Total | $518.00M | $553.00M | $522.00M | $502.00M | $518.00M | $532.00M | $1.49B | — |
Animal Health, Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s d&a?
- Merck & Co. (MRK) reported d&a of $1.49B in Q4 2025.
- How has Merck & Co.'s d&a changed year-over-year?
- Merck & Co.'s d&a increased by 186.0% year-over-year, from $522.00M to $1.49B.
- What is the long-term trend for Merck & Co.'s d&a?
- Over 4 years (2021 to 2025), Merck & Co.'s d&a has grown at a 17.9% compound annual growth rate (CAGR), from $1.58B to $3.05B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.